组蛋白去乙酰化酶抑制剂在外周T细胞淋巴瘤中的应用进展

杨明子; 刘卫平; 朱军

doi:10.3969/j.issn.1000-8179.2018.13.235

组蛋白去乙酰化酶抑制剂在外周T细胞淋巴瘤中的应用进展

doi: 10.3969/j.issn.1000-8179.2018.13.235

北京大学肿瘤医院暨北京市肿瘤防治研究所淋巴肿瘤内科，恶性肿瘤发病机制及转化研究教育部重点实验室（北京市100142）

基金项目:

首都卫生发展科研专项 2018-1-2151

CSCO-齐鲁肿瘤研究基金项目 Y-Q2017-035

北京市医院管理局“登峰”人才计划培养项目 DFL20151001

详细信息

作者简介:
杨明子专业方向为淋巴瘤的诊断及治疗。E-mail：yangmingzi_1993@163.com

朱军教授，主任医师，博士研究生导师。现任北京大学肿瘤医院党委书记，大内科主任，淋巴肿瘤内科主任。兼任中国临床肿瘤学会（CSCO）执委会常委，北京希思科临床肿瘤学研究基金会副理事长，中国免疫学会血液免疫专业分会副主任委员，中国临床肿瘤学会（CSCO）抗肿瘤药物安全管理专家委员会副主任委员，中国临床肿瘤学会（CSCO）中国抗淋巴瘤联盟主任委员，中国抗癌协会血液肿瘤专业委员会常委，中国老年学会老年肿瘤专业委员会常委，《淋巴瘤·白血病》期刊编委、《中国医院用药与评价》期刊编委会副主任、国家自然科学基金和863项目评审专家。北京市“十百千”卫生人才培养“十”层次人选。获得国家自然科学基金项目资助2项，北京市科委首都特色课题、北京市卫生局首发基金课题及北京市科委重点课题各1项，北京大学985Ⅲ期课题1项，并作为主要成员参与“863”和“973”重大专项课题各1项。在国内外核心期刊发表论文百余篇，先后参与制定2015年淋巴瘤NCCN指南（中文版），主译《淋巴瘤》等专著2部，参与撰写专著7部

通讯作者:
朱军 zhu-jun2017@outlook.com

计量
- 文章访问数: 108
- HTML全文浏览量: 2
- PDF下载量: 7
- 被引次数: 0
出版历程
- 收稿日期: 2018-03-09
- 修回日期: 2018-05-28
- 刊出日期: 2018-07-15

Advances in histone deacetylase inhibitors for the treatment of peripheral T-cell lymphoma

Department of Lymphoma, Beijing Cancer Hospital, Peking University School of Clinical Oncology, Beijing Institute for Cancer Research, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, China

Funds:

Capital's Funds for Health Improvement and Research 2018-1-2151

CSCO-QiLu Oncology Research Fund Y-Q2017-035

Beijing Municipal Administration of Hospitals' Ascent Plan DFL20151001

More Information

Corresponding author: Jun Zhu; zhu-jun2017@outlook.com

摘要

摘要: 外周T细胞淋巴瘤（peripheralTcelllymphoma，PTCL）是一类具有高度异质性的起源于成熟T细胞或NK细胞的恶性肿瘤，大多数类型侵袭性高、进展快，总体预后不佳。表观遗传修饰对PTCL在内的恶性肿瘤的发生发展起重要作用。目前与表观遗传调控相关的组蛋白去乙酰化酶抑制剂（histonedeacetylaseinhibitors，HDACi）已经用于PTCL的治疗，在单药及联合治疗时显示出良好的耐受性和治疗效果，其中伏立诺他、罗米地辛、贝利司他和西达本胺已先后被批准上市。本文对HDACi在PTCL治疗方面的应用进展进行综述。
- 表观遗传学 /
- 组蛋白去乙酰化酶抑制剂 /
- 外周T细胞淋巴瘤 /
- 治疗
Abstract: Peripheral T-cell lymphoma (PTCL) is a group of highly heterogeneous non-Hodgkin's lymphomas derived from mature T or NK cells. Most subtypes of PTCL are highly aggressive with rapid growth and poor prognosis. Recently, epigenetic modification has been reported to play an important role in the evolution and progression of cancers, especially PTCL. Therefore, as a novel antineoplastic agent, histone deacetylase inhibitor has already been used in treating PTCL. The histone deacetylase inhibitor with or without chemotherapy or other therapies showed good tolerance and significant efficacy. Several histone deacetylase inhibitors, such as vorinostat, romidepsin, belinostat, and chidamide, have been approved by the FDA or CFDA. This review summarizes the advances of using histone deacetylase inhibitors as an alternative anti-cancer therapeutic strategy for the treatment of PTCL.
- epigenetics /
- HDACi /
- PTCL /
- treatment

HTML全文

参考文献(22)

[1]	Savage KJ. Peripheral T-cell lymphomas[J]. Blood Rev, 2007, 21(4): 201-216. doi: 10.1016/j.blre.2007.03.001
[2]	Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T- cell lymphoma study: pathology findings and clinical outcomes[J]. J Clin Oncol, 2008, 26(25):4124-4130. doi: 10.1200/JCO.2008.16.4558
[3]	Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20):2375-2390. doi: 10.1182/blood-2016-01-643569
[4]	Qiu J. Epigenetics: unfinished symphony[J]. Nature, 2006, 441(7090): 143-145. doi: 10.1038/441143a
[5]	Pfister SX, Ashworth A. Marked for death: targeting epigenetic changes in cancer[J]. Nat Rev Drug Discov, 2017, 16(4):241-263. doi: 10.1038/nrd.2016.256
[6]	Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors[J]. Nat Rev Drug Discov, 2006, 5(9):769-784. doi: 10.1038/nrd2133
[7]	Lakshmaiah KC, Jacob LA, Aparna S, et al. Epigenetic therapy of cancer with histone deacetylase inhibitors[J]. J Cancer Res Ther, 2014, 10(3):469-478. http://cn.bing.com/academic/profile?id=9b3cf221d93208bdde295fcb913d308d&encoded=0&v=paper_preview&mkt=zh-cn
[8]	Beumer JH, TawbiH. Role of histone deacetylases and their inhibitors in cancer biology and treatment[J]. Curr Clin Pharmacol, 2010, 5(3):196-208. doi: 10.2174/157488410791498770
[9]	Oki Y, Younes A, Copeland A. PhaseⅠstudy of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma[J]. Br J Haematol, 2013, 162(1):138-141. doi: 10.1111/bjh.2013.162.issue-1
[10]	Budde LE, Zhang MM, Shustov AR, et al. A phaseⅠstudy of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma[J]. Br J Haematol, 2013, 161(2):183-191. doi: 10.1111/bjh.2013.161.issue-2
[11]	Nieto Y, Valdez BC, Thall PF. Vorinostat combined with high- dose gemcitabine, busulfan, and melphalan with autologous stem cell transplantation in patients with refractory lymphomas[J]. Biol Blood Marr Transpl, 2015, 21(11):1914-1920. doi: 10.1016/j.bbmt.2015.06.003
[12]	Jiang T, Wang F, Hu L, et al. Chidamide and decitabine can synergistically induce apoptosis of Hodgkin lymphoma cells by up-regulating the expression of PU.1 and KLF4[J]. Oncotarget. 2017, 8(44):77586- 77594. http://cn.bing.com/academic/profile?id=ead69bcdbcd313f5b68038eaf08cedbc&encoded=0&v=paper_preview&mkt=zh-cn
[13]	Stathis A, Hotte SJ, Chen EX, et al. PhaseⅠstudy of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas[J]. Clin Cancer Res, 2011, 17(6):1582- 1590. doi: 10.1158/1078-0432.CCR-10-1893
[14]	Hopfinger G, Nösslinger T, Lang A, et al. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase Ⅰ/Ⅱ trial[J]. Ann Hematol, 2014, 93(3):459-462. doi: 10.1007/s00277-014-2009-0
[15]	Dupuis J, Morschhauser F, Ghesquières H, et al. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phaseⅠb/2 study[J]. Lancet Haematol, 2015, 2(4):e160-e165. doi: 10.1016/S2352-3026(15)00023-X
[16]	Pellegrini C, Dodero A, Chiappella A, et al. A phase Ⅱ study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T- cell lymphoma patients [J]. J Hematol Oncol, 2016, 9(1):38. doi: 10.1186/s13045-016-0266-1
[17]	Mehta-Shah N, Lunning MA, Boruchov AM, et al. A phase Ⅰ/Ⅱ trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Activity in T- cell lymphoma[G]. J Clin Oncol, 2015, 33(15): 8521.
[18]	Kim SJ, Kim JH, Ki CS, et al. Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin[J]. Ann Oncol, 2016, 27(3):508-513. doi: 10.1093/annonc/mdv596
[19]	O'Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral T- cell lymphoma: results of the pivotal phase Ⅱ BELIEF (CLN-19) study[J]. J Clin Oncol, 2015, 33(23): 2492-2499. doi: 10.1200/JCO.2014.59.2782
[20]	Johnston PB, Cashen AF, Nikolinakos PG, et al. Safe and effective treatment of patients with peripheral T-cell lymphoma (PTCL) with the novel HDAC inhibitor, belinostat, in combination with CHOP: results of the bel-CHOP phase Ⅰ trial[J]. Blood, 2015, 128(126):253.
[21]	Shi Y, Jia B, Xu W, et al. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China[J]. J Hematol Oncol, 2017, 10(1):69. doi: 10.1186/s13045-017-0439-6
[22]	Ji MM, Huang YH, Huang JY, et al. Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified[J]. Haematologica, 2018, 103(4):679-687. doi: 10.3324/haematol.2017.182444